Product Liability & Toxic Torts

This week we focus on pharmaceutical litigation: a ruling that failure-to-warn claims brought against generic drug makers are pre-empted by federal law, a look at why drug manufacturers who comply with FDA labeling regulations are granted a rebuttable presumption that their labeling is adequate, and some practical pointers for litigators of product-liability cases.

This article requires premium access

This article requires premium access to The New Jersey Law Journal. Please sign in or subscribe to read the full text.